Published research on SS-31 / elamipretide: record counts, recent publications, reviews and registered studies, pulled from PubMed and ClinicalTrials.gov. Part of other.
Ask TinaTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Registered studies by status: 2 recruiting, 1 active not recruiting, 14 completed.
Number of PubMed records mentioning SS-31 / elamipretide, 2016 to 2026 (2026 is year to date).
Most recently started of 21 ClinicalTrials.gov entries.
Clinical Trial in Patients With Barth Syndrome- 4TAZPowerNCT07531251 · Recruiting · Phase 4 · started 2026-07-02Study of Healthy Aging and Physical Function With ElamipretideNCT07275424 · Recruiting · Phase 2 · started 2025-11-26ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)NCT06373731 · Active Not Recruiting · Phase 3 · started 2024-05-30Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)NCT05162768 · Completed · Phase 3 · started 2022-04-29FRDA Investigator Initiated Study (IIS) With ElamipretideNCT05168774 · Completed · Phase 1 / Phase 2 · started 2022-03-03ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GANCT03891875 · Completed · Phase 2 · started 2019-03-27A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label ExtensionNCT03323749 · Terminated · Phase 3 · started 2017-10-09A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth SyndromeNCT03098797 · Completed · Phase 2 / Phase 3 · started 2017-07-05Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)NCT02976038 · Terminated · Phase 2 · started 2016-12An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular DegenerationNCT02848313 · Completed · Phase 1 · started 2016-10-28A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart FailureNCT02914665 · Completed · Phase 2 · started 2016-10-20A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection FractionNCT02814097 · Completed · Phase 2 · started 2016-09-02Positive coverage and opinions: this section collects news and commentary that read favorably.
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialEli Lilly and Company (investor.lilly.com) · May 21, 2026Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1CEli Lilly and Company (via PR Newswire) · Jul 23, 2026Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetesEli Lilly and Company (via PR Newswire) · Sep 29, 2026Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trialEli Lilly and Company (investor.lilly.com) · Dec 11, 2025Eli Lilly to offer early access to next-gen obesity drug to some patientsReuters · Aug 3, 2026FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictionsEli Lilly and Company (investor.lilly.com) · Apr 1, 2026Eli Lilly press release archiveEli Lilly and Company · CurrentNovo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trialNovo Nordisk (via GlobeNewswire) · Sep 21, 2026Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesBoehringer Ingelheim (via GlobeNewswire) · Oct 1, 2026RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONSAmgen · Jun 2025Primary data for your own interpretation: published studies and regulator documents. No publisher opinion pieces.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med · 2026 Apr 12 · Mendias CL et al. · PubMedIs an emerging pharmacotherapeutic era for rare mitochondrial diseases here?Cell Metab · 2026 Jun 2 · Bedoyan JK et al. · PubMedTherapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci · 2026 Apr 27 · Renke G et al. · PubMedLong-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.Genet Med · 2024 Apr 8 · Thompson WR et al. · PubMedEfficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.Neurology · 2023 Jun 2 · Karaa A et al. · PubMedAsk Tina for links to further coverageTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Third-party links, listed for reference. Educational information only, not medical advice. Hypnotic Dose does not endorse any product.